CN115902222A - Breast cancer chemotherapy risk scoring model and construction method and system thereof - Google Patents
Breast cancer chemotherapy risk scoring model and construction method and system thereof Download PDFInfo
- Publication number
- CN115902222A CN115902222A CN202211377131.2A CN202211377131A CN115902222A CN 115902222 A CN115902222 A CN 115902222A CN 202211377131 A CN202211377131 A CN 202211377131A CN 115902222 A CN115902222 A CN 115902222A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- risk score
- risk
- growth factor
- epidermal growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 87
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 87
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 50
- 238000010276 construction Methods 0.000 title abstract description 5
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 32
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 32
- 210000001519 tissue Anatomy 0.000 claims abstract description 31
- 108091008039 hormone receptors Proteins 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 17
- 102100026540 Cathepsin L2 Human genes 0.000 claims abstract description 16
- 101710169274 Cathepsin L2 Proteins 0.000 claims abstract description 16
- 108010060385 Cyclin B1 Proteins 0.000 claims abstract description 16
- 102000000763 Survivin Human genes 0.000 claims abstract description 14
- 108010002687 Survivin Proteins 0.000 claims abstract description 14
- 239000003147 molecular marker Substances 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 210000003855 cell nucleus Anatomy 0.000 claims abstract description 7
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 6
- 238000011002 quantification Methods 0.000 claims abstract description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 18
- 238000010186 staining Methods 0.000 claims description 16
- 239000005441 aurora Substances 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 8
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 claims description 7
- 102100028847 Stromelysin-3 Human genes 0.000 claims description 7
- 210000004940 nucleus Anatomy 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 5
- 102000003992 Peroxidases Human genes 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000000805 cytoplasm Anatomy 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 4
- 101150028074 2 gene Proteins 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 3
- 238000012151 immunohistochemical method Methods 0.000 claims description 3
- 238000007901 in situ hybridization Methods 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 238000001000 micrograph Methods 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 2
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 4
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 102100025803 Progesterone receptor Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 102000008178 Cyclin B1 Human genes 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000001993 wax Substances 0.000 description 8
- 239000008399 tap water Substances 0.000 description 7
- 235000020679 tap water Nutrition 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000008096 xylene Substances 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000004018 waxing Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical class [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to the technical field of breast cancer treatment, in particular to a breast cancer chemotherapy risk scoring model and a construction method and a system thereof; the method comprises the following steps: obtaining a breast cancer tissue specimen; selecting the breast cancer tissue specimen which accords with hormone receptor positive and epidermal growth factor receptor 2 negative for detection; calculating the percentage of Ki 67-positive stained cells in the breast cancer cell nucleus; respectively calculating the molecular marker expression quantification of Aurora A, survivin, cyclin B1, cathepsin L2 and MMP 11; establishing a breast cancer chemotherapy risk scoring model by taking a risk function as the weight of each protein expression based on the linear combination of the regression coefficient of the multiple Cox regression model multiplied by the regression coefficient of the expression level; provides a reference basis for treating breast cancer patients by adopting a chemotherapy method, and avoids blind chemotherapy of the breast cancer patients.
Description
Technical Field
The invention relates to the technical field of breast cancer treatment, in particular to a breast cancer chemotherapy risk scoring model and a construction method and a system thereof.
Background
The incidence of breast cancer worldwide has been on the rise since the end of the 20 th century 70 s. 1 of 8 women in the United states suffered from breast cancer in their lifetime. China is not a high-incidence country of breast cancer, but is not optimistic, and the growth rate of the incidence of breast cancer in China is 1-2% higher than that of the high-incidence country in recent years. According to 2009 breast cancer onset data published by the disease prevention and control agency of the national cancer center and the ministry of health in 2012, it is shown that: the incidence of breast cancer of women in tumor registration areas in the whole country is 1 st of malignant tumors of women, the incidence (thickness) of breast cancer of women is 42.55/10 ten thousand in total in the whole country, 51.91/10 ten thousand in cities and 23.12/10 ten thousand in rural areas.
While treatment of breast cancer involves chemotherapy treatment, chemotherapy helps to reduce the recurrence rate and mortality rate of early breast cancer patients, but not all patients can benefit the chemotherapy, and chemotherapy may also cause over-treatment of some breast cancer patients, so certain evaluation measures are still required for whether the breast cancer patients are treated by chemotherapy.
Disclosure of Invention
In view of the above-mentioned shortcomings of the prior art, the present invention aims to provide a breast cancer chemotherapy risk scoring model, and a method and a system for constructing the same, so as to provide an evaluation mode for whether a breast cancer patient is treated by chemotherapy.
In order to solve the problems, the invention adopts the following technical scheme:
in a first aspect, the invention provides a method for constructing a hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk score model, comprising the following steps:
obtaining a breast cancer tissue specimen;
selecting the breast cancer tissue specimen which accords with hormone receptor positive and epidermal growth factor receptor 2 negative for detection;
calculating the percentage of Ki67 positive staining cells in the breast cancer cell nucleus;
respectively calculating the expression quantification of the molecular markers of Aurora A, survivin, cyclin B1, cathepsin L2 and MMP 11;
and (3) establishing a breast cancer chemotherapy risk scoring model by taking the risk function as the weight of each protein expression based on the linear combination of the regression coefficient of the multiple Cox regression model multiplied by the regression coefficient of the expression level.
Further, the obtaining a breast cancer tissue specimen comprises:
obtaining a breast cancer tissue specimen, pretreating, and then, dipping wax and slicing;
dewaxing the section, staining a nucleus by hematoxylin, staining cytoplasm by eosin, dehydrating and sealing the section, and determining a chip collection point on the section to prepare an immunoassay specimen;
dewaxing an immunity test sample, repairing antigen, sealing goat serum, then dropwise adding primary antibody, secondary antibody and streptavidin peroxidase, performing DAB color development, counterstaining with hematoxylin, and performing microscope image acquisition.
Furthermore, the proportion of tumor cells with positive hormone receptors, which are expressed by estrogen and progestogen receptor proteins in nuclei and have brown particles, in all the tumor cells is more than or equal to 1 percent.
Further, the epidermal growth factor receptor 2 negative detects the expression level of the epidermal growth factor receptor 2 protein by an immunohistochemical method, detects the amplification level of the epidermal growth factor receptor 2 gene by an in situ hybridization method, and defines IHC0/1+ as negative.
Further, the calculation of the expression of the molecular markers of Aurora a, survivin, cyclin B1, cathepsin L2 and MMP11, respectively, was quantified as the average percentage of positively stained cells of the Aurora a, survivin, cyclin B1, cathepsin L2 and MMP11, respectively, to the total number of malignant cells.
Further, the risk score calculation formula of the risk score model is as follows: risk score =1.2 × expression of cathepsin L2 +1.3 × expression of mmp11 + expression of 1.4 × cyclin B1 + expression of 1.3 × aurora a + expression of 1.2 × expression of surfvin + expression of 1.4 × ki67.
In a second aspect, the present invention provides a system for constructing a risk score model of breast cancer chemotherapy with hormone receptor positive and epidermal growth factor receptor 2 negative, comprising:
the specimen preparation module is used for obtaining a breast cancer tissue specimen;
the breast cancer tissue specimen screening module is used for selecting the breast cancer tissue specimen which accords with hormone receptor positive and epidermal growth factor receptor 2 negative for detection;
the percentage calculation module of the Ki67 positive staining cells is used for calculating the percentage of the Ki67 positive staining cells in the cell nucleus of the breast cancer;
a molecular marker expression quantification calculation module for calculating molecular marker expression quantification of Aurora A, survivin, cyclin B1, cathepsin L2 and MMP11, respectively;
and the risk scoring model establishing module is used for establishing a breast cancer chemotherapy risk scoring model by taking the risk function as the weight of each protein expression based on the linear combination of the regression coefficient of the multiple Cox regression model multiplied by the regression coefficient of the expression level.
In a third aspect, the invention provides a breast cancer chemotherapy risk score model constructed by the method for constructing the hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk score model.
Further, drawing a working curve of the subject through SP 33.0, calculating a john index, taking a corresponding value of an interception point corresponding to the maximum john index as a risk score critical value, and if the risk score calculated by the breast cancer chemotherapy risk score model is greater than the risk score critical value, judging the breast cancer chemotherapy risk score model to be high-risk; otherwise, the risk is low.
Further, the risk score cutoff is 2.16.
The invention has the beneficial effects that: the invention provides a breast cancer chemotherapy risk scoring model and a construction method and a system thereof, wherein the breast cancer chemotherapy risk scoring model is established by calculating the expression quantities of breast cancer cells Ki67, aurora A, survivin, cyclin B1, cathepsin L2 and MMP11 and based on a multivariate Cox regression model, so that a reference basis is provided for whether a breast cancer patient adopts a chemotherapy means for treatment, and the condition that the breast cancer patient is blind in chemotherapy and is unfavorable to the body is avoided.
Drawings
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be further described in detail with reference to the accompanying drawings, in which:
FIG. 1 is a schematic flow chart of a method for constructing a risk score model of breast cancer chemotherapy with hormone receptor positive and epidermal growth factor receptor 2 negative according to an embodiment of the present invention.
FIG. 2 is a schematic diagram of a system for constructing a risk score model of breast cancer chemotherapy with hormone receptor positive and epidermal growth factor receptor 2 negative according to an embodiment of the present invention.
Detailed Description
The present invention will be described in further detail with reference to specific examples.
It should be noted that these examples are only for illustrating the present invention, and not for limiting the present invention, and the simple modification of the method based on the idea of the present invention is within the protection scope of the present invention.
Referring to fig. 1, a method for constructing a risk score model of breast cancer chemotherapy with hormone receptor positive and epidermal growth factor receptor 2 negative includes:
s100, obtaining a breast cancer tissue specimen;
s200, selecting the breast cancer tissue specimen which accords with hormone receptor positive and epidermal growth factor receptor 2 negative for detection;
s300, calculating the percentage of Ki67 positive staining cells in the breast cancer cell nucleus;
s400, respectively calculating the expression quantification of the molecular markers of Aurora A, survivin, cyclin B1, cathepsin L2 and MMP 11;
s500, based on the linear combination of the regression coefficients of the multiple Cox regression model and the regression coefficients of the expression level of the multiple Cox regression model, taking the risk function as the weight of each protein expression, and establishing a breast cancer chemotherapy risk scoring model.
Wherein S100 comprises:
s101, obtaining a breast cancer tissue specimen, pretreating, and then, dipping wax and slicing.
The method specifically comprises the following steps:
fresh tissue from the surgically excised specimens was immersed in 4% paraformaldehyde fixing solution and fixing continued for at least 24 hours. After fixation, the tissue was removed from the fixative, the site of evidence of necrosis and hemorrhage was removed with a scalpel in a fume hood, the target tissue was trimmed, the repaired tissue was marked, and placed in a dehydration box. Dewaxing and soaking: and (4) placing the dewatering box in a hanging basket, and then placing the box in a dewatering machine for dewatering according to the gradient of the alcohol concentration. 75% alcohol for 4 hours, 85% alcohol for 2 hours, 90% alcohol for 2 hours, 95% alcohol for 1 hour, absolute ethanol I for 30 minutes, absolute ethanol II for 30 minutes, xylene I for 10 minutes, xylene II for 10 minutes.
Wax dipping: paraffin wax was melted and the temperature was maintained at about 57 ℃. A total of three passes of waxing are required, the first time of waxing is about 15 minutes, and the next two passes of waxing can be properly extended to 30min-1h. Embedding: the melted wax was poured into the mold, the tissue was placed in, paraffin was then solidified, and then placed in the embedding frame for labeling. It was cooled on a-20 ℃ freezer table. After the wax solidified, it was removed from the embedding frame and the wax block was trimmed. Slicing: the wax block was sliced on a paraffin slicer to a thickness of 4 μm. The sections were then floated on a paraffin slicer, flattened in warm water at 40 ℃, scooped up with a glass slide, and then baked in an oven at 60 ℃. After baking the water and wax, it was removed and stored at room temperature for later use.
S102, dewaxing the section, staining nuclei with hematoxylin, staining cytoplasm with eosin, dehydrating and sealing the section, and determining a chip collection point on the section to obtain an immune test specimen.
The method specifically comprises the following steps:
placing the slices into dimethylbenzene I for 15 minutes, dimethylbenzene II for 15 minutes, dimethylbenzene III for 15 minutes, absolute ethyl alcohol I for 10 minutes, absolute ethyl alcohol II for 10 minutes, 90% alcohol for 5 minutes, 80% alcohol for 5 minutes, and 70% alcohol for washing for 5 minutes. And (3) hematoxylin nuclear staining: hematoxylin staining for 5 minutes, washing with tap water, distinguishing 1% hydrochloric acid from alcohol, washing with tap water, recovering blue, and washing with tap water. Eosin staining of cytoplasm: the slices were dehydrated in 70%, 80%, 90% ethanol for 3 min, and placed in eosin staining solution for 5 min. And (4) dewatering and sealing the sheet: the slices are sequentially made into absolute ethyl alcohol I for 5 minutes, absolute ethyl alcohol II for 5 minutes, absolute ethyl alcohol III for 5 minutes, xylene I for 5 minutes, xylene II for 5 minutes, and the slices are transparent, neutral and rubber-sealed for 5 minutes. And selecting a representative area on the section for microscopic examination, and determining the chip acquisition point.
S103, dewaxing an immunoassay sample, repairing antigen, sealing goat serum, then dripping primary antibody, secondary antibody and streptavidin peroxidase to perform DAB color development, performing hematoxylin counterstain, and performing microscope image acquisition.
The method specifically comprises the following steps:
paraffin section and dewaxing, placing the baked tissue chips in the following sequence: xylene I, II each 15 minutes, xylene III 15 minutes, absolute ethanol I, II each 10 minutes, 90%, 80%, 70% ethanol each 5 minutes, and finally 3 washes with PBS each 3 minutes.
Putting the chips into 3% 2 O 2 Incubated in the dark at room temperature for 10 minutes, then washed 3 times with PBS for 3 minutes each.
Antigen retrieval: immersing the tissue slices into a repairing box with EDTA antigen repairing buffer solution, and placing the repairing box in an autoclave for high-pressure water bath. After boiling, heating was continued for 5 minutes. In this process, the buffer should be prevented from excessive evaporation, and the sections should not be dried. After cooling, the slides were placed in PBS (pH 7.4) and washed 3 times with PBS on a destaining shaker for 3 minutes each.
Sealing goat serum: a circle was drawn around the tissue with a pen to prevent antibody run-off, goat serum was added dropwise to the circle and incubated at room temperature for 20 min.
A proportion of primary antibody was added dropwise, the sections were kept flat in a moist box to prevent evaporation of antibody, and incubated overnight at 4 ℃.
And (4) dropwise adding a secondary antibody: the tissue chips were removed and washed 3 times with PBS for 3 minutes each. After the sections were slightly dried, the corresponding secondary antibody was added dropwise and incubated at room temperature for 30 minutes. The PBS was washed 3 times with shaking for 3 minutes each.
Dropping streptavidin peroxidase: streptavidin peroxidase was added dropwise, incubated at room temperature for 15 minutes and then washed 3 times with PBS, 3 minutes each.
DAB color development: DAB color reagent 1. The brown-yellow color is a positive stain, and the sections are rinsed with tap water to stop the reaction when the color deepens.
Counterstaining with hematoxylin for 5 minutes, washing in tap water, differentiation in 1% ethanol hydrochloride for several seconds, then washing in tap water, reduction to blue with saturated lithium carbonate for 2 minutes, and then washing with tap water.
Dewatering and fixing: the slices were placed in 70%, 80%, 90% ethanol for 3 minutes each, and in absolute ethanol I, II for 5 minutes each, until dehydrated and became transparent, and the slices were taken out and sealed with neutral gum.
Image acquisition and analysis was performed under a microscope.
In step S200, the proportion of the tumor cells with positive hormone receptors, which are expressed by estrogen and progestogen receptor proteins in nuclei and have brown particles, in all the tumor cells is more than or equal to 1%.
The epidermal growth factor receptor 2 negative characteristic is that the expression level of epidermal growth factor receptor 2 protein is detected by an immunohistochemical method, the amplification level of epidermal growth factor receptor 2 gene is detected by an in-situ hybridization method, and IHC0/1+ is defined as negative.
In step S400, the molecular marker expression quantities of Aurora a, survivin, cyclin B1, cathepsin L2, and MMP11 are calculated as the average percentage of the total number of malignant cells in which the positively stained cells account for Aurora a, survivin, cyclin B1, cathepsin L2, and MMP11, respectively.
In step S500, the risk score calculation formula of the risk score model is as follows: risk score =1.2 × expression of cathepsin L2 +1.3 × expression of mmp11 + expression of 1.4 × cyclin B1 + expression of 1.3 × aurora a + expression of 1.2 × expression of surfvin + expression of 1.4 × ki67.
Referring to fig. 2, a system for constructing a risk score model of breast cancer chemotherapy with hormone receptor positive and epidermal growth factor receptor 2 negative includes:
the specimen preparation module is used for obtaining a breast cancer tissue specimen;
the breast cancer tissue specimen screening module is used for selecting the breast cancer tissue specimen which accords with hormone receptor positive and epidermal growth factor receptor 2 negative for detection;
the percentage calculation module of the Ki67 positive staining cells is used for calculating the percentage of the Ki67 positive staining cells in the cell nucleus of the breast cancer;
the molecular marker expression quantitative calculation module is used for respectively calculating the molecular marker expression quantitative of Aurora A, survivin, cyclin B1, cathepsin L2 and MMP 11;
and the risk scoring model establishing module is used for establishing a breast cancer chemotherapy risk scoring model by taking the risk function as the weight of each protein expression based on the linear combination of the regression coefficients of the multiple Cox regression model multiplied by the regression coefficients of the expression level.
A breast cancer chemotherapy risk scoring model constructed by the method for constructing the hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk scoring model.
Drawing a working curve of a subject through SP 33.0, calculating a john index, taking a corresponding value of an interception point corresponding to the maximum john index as a risk score critical value, and if the risk score calculated by the breast cancer chemotherapy risk score model is greater than the risk score critical value, judging that the risk is high; otherwise, the risk is low.
Wherein the subject's criteria are as follows:
postmenopausal or premenopausal/perimenopausal female patients;
pathologically confirmed early primary invasive breast cancer with positive hormone receptor and negative HER 2;
before operation, radiotherapy, new auxiliary chemotherapy, endocrine treatment or targeted treatment is not carried out;
the patients receive systemic endocrine therapy.
The risk score cutoff value was calculated to be 2.16.
Finally, it is noted that the above-mentioned embodiments illustrate rather than limit the invention, and that, while the invention has been described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (10)
1. A method for constructing a hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk score model is characterized by comprising the following steps:
obtaining a breast cancer tissue specimen;
selecting the breast cancer tissue specimen which accords with hormone receptor positive and epidermal growth factor receptor 2 negative for detection;
calculating the percentage of Ki 67-positive stained cells in the breast cancer cell nucleus;
respectively calculating the molecular marker expression quantification of Aurora A, survivin, cyclin B1, cathepsin L2 and MMP 11;
and (3) establishing a breast cancer chemotherapy risk scoring model by taking the risk function as the weight of each protein expression based on the linear combination of the regression coefficient of the multiple Cox regression model multiplied by the regression coefficient of the expression level.
2. The method for constructing a risk score model for breast cancer chemotherapy with hormone receptor positive and epidermal growth factor receptor 2 negative according to claim 1, wherein said obtaining a tissue specimen of breast cancer comprises:
obtaining a breast cancer tissue specimen, pretreating, then, dipping wax and slicing;
dewaxing the section, staining a nucleus by hematoxylin, staining cytoplasm by eosin, dehydrating and sealing the section, and determining a chip collection point on the section to prepare an immunoassay specimen;
dewaxing an immunity test sample, repairing antigen, sealing goat serum, then dropwise adding primary antibody, secondary antibody and streptavidin peroxidase, performing DAB color development, counterstaining with hematoxylin, and performing microscope image acquisition.
3. The method for constructing the hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk score model according to claim 1, wherein the proportion of tumor cells with the hormone receptor positive being the nucleus in which the estrogen and progesterone receptor proteins are expressed and brown particles appear is greater than or equal to 1% of all tumor cells.
4. The method for constructing the hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk score model according to claim 1, wherein the epidermal growth factor receptor 2 negative is characterized in that the expression level of epidermal growth factor receptor 2 protein is detected by an immunohistochemical method, the amplification level of epidermal growth factor receptor 2 gene is detected by an in situ hybridization method, and IHC0/1+ is defined as negative.
5. The method for constructing a hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk score model according to claim 1, wherein the molecular marker expression quantities of Aurora a, survivin, cyclin B1, cathepsin L2 and MMP11 are calculated as the average percentage of positively stained cells in the total number of malignant cells.
6. The method for constructing a risk score model of breast cancer chemotherapy, which is positive for hormone receptor and negative for epidermal growth factor receptor 2 according to claim 1, wherein the risk score is calculated by the risk score model according to the following formula: risk score =1.2 × cathepsin L2 expression +1.3 × mmp11 expression +1.4 × cyclin B1 expression +1.3 × aurora a expression +1.2 × survivin expression +1.4 × ki67 expression.
7. A system for constructing a hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk score model is characterized by comprising:
the specimen preparation module is used for obtaining a breast cancer tissue specimen;
the breast cancer tissue specimen screening module is used for selecting the breast cancer tissue specimen which accords with hormone receptor positive and epidermal growth factor receptor 2 negative for detection;
the percentage calculation module of the Ki67 positive staining cells is used for calculating the percentage of the Ki67 positive staining cells in the cell nucleus of the breast cancer;
the molecular marker expression quantitative calculation module is used for respectively calculating the molecular marker expression quantitative of Aurora A, survivin, cyclin B1, cathepsin L2 and MMP 11;
and the risk scoring model establishing module is used for establishing a breast cancer chemotherapy risk scoring model by taking the risk function as the weight of each protein expression based on the linear combination of the regression coefficients of the multiple Cox regression model multiplied by the regression coefficients of the expression level.
8. A breast cancer chemotherapy risk scoring model constructed by a method for constructing a hormone receptor positive and epidermal growth factor receptor 2 negative breast cancer chemotherapy risk scoring model.
9. The breast cancer chemotherapy risk score model according to claim 8, further comprising plotting a subject working curve by SP 33.0, calculating a john index, using the corresponding value of the cut-off point corresponding to the maximum john index as a risk score critical value, and determining as high risk if the risk score calculated by the breast cancer chemotherapy risk score model is greater than the risk score critical value; otherwise, the risk is low.
10. The breast cancer chemotherapy risk score model of claim 9, wherein the risk score cut-off value is 2.16.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211377131.2A CN115902222A (en) | 2022-11-04 | 2022-11-04 | Breast cancer chemotherapy risk scoring model and construction method and system thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211377131.2A CN115902222A (en) | 2022-11-04 | 2022-11-04 | Breast cancer chemotherapy risk scoring model and construction method and system thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115902222A true CN115902222A (en) | 2023-04-04 |
Family
ID=86481647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211377131.2A Pending CN115902222A (en) | 2022-11-04 | 2022-11-04 | Breast cancer chemotherapy risk scoring model and construction method and system thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115902222A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019077080A1 (en) * | 2017-10-19 | 2019-04-25 | Universite Claude Bernard Lyon 1 | Evaluation of the risk of metastatic relapse in breast cancer patients |
| CN111679072A (en) * | 2020-06-15 | 2020-09-18 | 温州医科大学 | Application of KDM6B protein in breast cancer prognosis evaluation kit and diagnosis kit |
| CN114807370A (en) * | 2022-04-29 | 2022-07-29 | 中国医学科学院肿瘤医院 | Novel model for accurate prediction of curative effect of breast cancer immunotherapy and application thereof |
-
2022
- 2022-11-04 CN CN202211377131.2A patent/CN115902222A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019077080A1 (en) * | 2017-10-19 | 2019-04-25 | Universite Claude Bernard Lyon 1 | Evaluation of the risk of metastatic relapse in breast cancer patients |
| CN111679072A (en) * | 2020-06-15 | 2020-09-18 | 温州医科大学 | Application of KDM6B protein in breast cancer prognosis evaluation kit and diagnosis kit |
| CN114807370A (en) * | 2022-04-29 | 2022-07-29 | 中国医学科学院肿瘤医院 | Novel model for accurate prediction of curative effect of breast cancer immunotherapy and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| JIAMAN LIN等: "Omission of Chemotherapy in HR + /HER2 −Early Invasive Breast Cancer Based on Combined 6-IHC Score?", CLINICAL BREAST CANCER, vol. 21, no. 5, pages 565 * |
| 林嘉曼: "HR+/HER2-早期乳腺癌免除化疗：基于免疫组化6-IHC综合评分对比21基因检测", 中国博士学位论文全文数据库 医药卫生科技辑(月刊), vol. 2022, no. 4, pages 1 - 36 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112326961B (en) | Analysis method and storage device for proportion of PD-L1 positive tumor cells in non-small cell lung cancer | |
| CN107085106B (en) | Detection reagent and kit for prostate cancer progression prognosis | |
| CN111679072B (en) | Application of KDM6B protein in breast cancer prognosis evaluation kit and diagnosis kit | |
| CN105510600A (en) | Method for detecting ER gene of peripheral blood circulating tumor cells of patient suffering from advanced breast cancer | |
| WO2023035728A1 (en) | Method for generating training data based on immunohistochemistry, and storage device | |
| CN104569397A (en) | Quality control sample for detecting breast cancer and preparation method of quality control sample | |
| CN105606823A (en) | Detection method for PR genes of circulating tumor cells in peripheral blood of later-period breast cancer patient | |
| CN113011257A (en) | Breast cancer immunohistochemical artificial intelligence interpretation method | |
| CN113834941B (en) | Marker for prognosis diagnosis of colon cancer based on B cell expression and application thereof | |
| CN113466458A (en) | Application of GPX4, NOX1 and ACSL4 in colorectal cancer prognosis evaluation | |
| CN116593262B (en) | Molecular marker detection product based on PDX/PDTX tumor living tissue biological sample and database and preparation method thereof | |
| CN115902222A (en) | Breast cancer chemotherapy risk scoring model and construction method and system thereof | |
| CN111551720A (en) | Method for detecting OGN protein expression and application thereof in gastric cancer auxiliary diagnosis | |
| CN116735875B (en) | Application of protein INF2 in preparation of liver cancer diagnosis marker | |
| CN103926408A (en) | Kit for forecasting NSCLC (non-small-cell lung cancer) patient prognosis and application of osteopontin acting as specific marker | |
| CN110244058A (en) | ENPP1 is preparing the application in high-level serous ovarian cancer diagnosis and prognosis kit | |
| CN111948395A (en) | Quadruple marker for diagnosing immune regulation subtype of triple negative breast cancer and application thereof | |
| CN112229997B (en) | Prognostic diagnosis marker Claudin23 for ovarian cancer and application thereof | |
| CN107271671A (en) | One kind prediction ER（+）The kit and system of neoadjuvant chemotherapy in breast effect | |
| CN114113084A (en) | Real-time accompanying film reading method based on digital pathological image and storage device | |
| CN107782903B (en) | Method for evaluating malignancy degree of cervical squamous cell carcinoma through positive expression condition of Sufu protein | |
| CN105606824A (en) | Detection method for Her-2 genes of circulating tumor cells in peripheral blood of later-period breast cancer patient | |
| CN105911281A (en) | Method for early warning breast cancer metastasis based on ZEB-1 and ZEB-2 as markers | |
| CN112649614A (en) | Application of CD8+ tumor infiltrating lymphocytes as markers in prognosis of esophageal small cell carcinoma | |
| CN114235805B (en) | System for prognosis evaluation of pancreatic solid pseudopapilloma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230404 |